Clinical course of advanced non-small cell lung cancer (NSCLC) patients (pts) experiencing hypertension (HTN) during treatment (TX) with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P) on E4599.
8042 Background: B is a monoclonal antibody that targets VEGF with demonstrated efficacy in combination with PC for the TX of advanced NSCLC. Administration of B is thought to decrease nitrous oxide synthesis and lead to HTN, one of the known toxicities associated with PCB on E4599. This side effect...
| Publicado en: | Journal of Clinical Oncology Vol. 27; pp. 8042 - 8043 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
5/21/2009 Supplement Part 1 of 2
|
| Acceso en línea: | Ver este registro en EBSCOhost |